Product image of Letrozole Accord (Letrozole) supplied by GNH India

Letrozole Accord

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Accord (Letrozole)

Letrozole, the active ingredient in Letrozole Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone‑receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for metastatic disease.

GNH India supplies Letrozole Accord as a licensed, GDP‑compliant international pharmaceutical product serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains and responsive technical support throughout the procurement process.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in the management of breast cancer, targeting estrogen‑dependent disease pathways.

  • Hormone receptor‑positive early‑stage breast cancer: improves disease‑free survival as adjuvant therapy.
  • Hormone receptor‑positive metastatic breast cancer: delays disease progression as first‑line endocrine treatment.
  • Postmenopausal estrogen‑dependent breast cancer: lowers circulating estrogen to inhibit tumor growth.

How It Works

  • Letrozole selectively and non‑steroidally inhibits the aromatase enzyme (CYP19A1), which converts androstenedione and testosterone to estrone and estradiol in peripheral tissues. By blocking this conversion, systemic estrogen concentrations fall markedly, depriving estrogen‑dependent tumor cells of a growth stimulus. The inhibition is reversible and dose‑dependent, providing sustained estrogen suppression in postmenopausal patients.

Side Effects

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Hot flashes: transient feeling of warmth and sweating.
  • Arthralgia: joint pain or stiffness.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Severe liver injury: marked elevation of liver enzymes or hepatitis.

Precautions & Warnings

When prescribing Letrozole, clinicians should consider several precautionary measures to minimise risk and ensure safe use.

  • Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation.
  • Cardiovascular assessment: evaluate risk factors for thrombosis and heart disease before initiation.
  • Liver function testing: perform baseline and periodic liver enzyme tests.
  • Drug interactions review: check for concomitant medications that may affect aromatase inhibition.
  • Pregnancy contraindication: avoid use in pregnant or breastfeeding women; letrozole is category X.
  • Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels.
  • Tamoxifen: concurrent use may antagonize endocrine effects.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): increased risk of bleeding; monitor INR.
  • SSRIs/SNRIs (fluoxetine, venlafaxine): may affect estrogen metabolism; observe for side effects.
  • Hormonal contraceptives: reduced efficacy; advise alternative contraception.

Frequently Asked Questions

Letrozole Accord is prescribed for hormone‑receptor‑positive breast cancer in postmenopausal women. It is used as adjuvant therapy after surgery to reduce recurrence risk and as first‑line treatment for metastatic disease to delay tumor progression.

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. This inhibition sharply lowers circulating estrogen levels, depriving estrogen‑dependent breast cancer cells of a key growth signal.

The specific dose of Letrozole Accord is determined by the treating physician based on the patient’s clinical condition, treatment setting and regulatory guidelines. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy and should not be used by breastfeeding women. It can cause fetal harm, and alternative therapies should be considered for women who are pregnant or lactating.

To order Letrozole Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Letrozole, anastrozole and exemestane are the three main aromatase inhibitors. Letrozole is often considered the most potent inhibitor of estrogen synthesis, offering slightly higher estrogen suppression, while anastrozole has a similar safety profile and exemestane is a steroidal inhibitor with a different metabolic pathway.

Letrozole tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Letrozole is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, split or chew the tablet unless specifically instructed by a healthcare professional.

The most serious risks associated with Letrozole include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism) and severe liver injury. Patients should report sudden leg swelling, chest pain, shortness of breath, or signs of liver dysfunction such as jaundice or dark urine to their physician promptly.

Letrozole should not be used by pregnant or breastfeeding women, premenopausal patients without ovarian suppression, individuals with known hypersensitivity to letrozole or any component of the formulation, and patients with severe liver impairment where the drug’s metabolism could be compromised.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT